Nonimmune complexed HCV RNA titer in serum as a predictor of interferon response in patients with chronic hepatitis C

American Journal of Gastroenterology

Volumn 98, Issue 3, 2003, Pages 645-652

  Fujita, Naoki ^a   Kaito, Masahiko ^b   Takeo, Masaki ^b   Iwasa, Motoh ^b   Ikoma, Jiro ^b   Watanabe, Shozo ^b   Adachi, Yukihiko ^b  

^a MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AMINOTRANSFERASE; BETA INTERFERON; IMMUNOGLOBULIN; IMMUNOGLOBULIN ANTIBODY; VIRUS RNA;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLOOD; CHRONIC DISEASE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOPRECIPITATION; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEPARATION TECHNIQUE; SERUM; STAGING; VIRUS PARTICLE;

EID: 0037344034     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2003.07330.x     Document Type: Article

References (39)

1. Kiyosawa K, Sodeyama T, Tanaka E, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virus. Hepatology 1990;12:671-5.
2. Alter MJ, Margolis HS, Krawczynski K, et al., for the Sentinel Counties Chronic Non-A, Non-B Hepatitis Study Team. The natural history of community-acquired hepatitis C in the United States. N Engl J Med 1992;327:1899-905.
3. Davis GL, Balart LA, Schiff ER, et al., and the Hepatitis Interventional Therapy Group. Treatment of chronic hepatitis C with recombinant interferon alfa: A multicenter randomized, controlled trial. N Engl J Med 1989;321:1501-6.
4. Di Bisceglie AM, Martin P, Kassianides C, et al. Recombinant interferon alfa therapy for chronic hepatitis C: A randomized, double-blind, placebo- controlled trial. N Engl J Med 1989; 321:1506-10.
5. Reichard O, Norkrans G, Fryden A, et al., for the Swedish Study Group. Randomized, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C. Lancet 1998;351:83-7.
6. Shiffman ML, Hofmann CM, Gabbay J, et al. Treatment of chronic hepatitis C in patients who failed interferon monotherapy: Effects of higher doses of interferon and ribavirin combination therapy. Am J Gastroenterol 2000;95:2399-400.
7. Jensen DM, Krawitt EL, Keeffe EB, et al. Biochemical and viral response to consensus interferon (CIFN) therapy in chronic hepatitis C patients: Effect of baseline viral concentration. Am J Gastroenterol 1999;94:3583-8.
8. Kohara M, Tanaka T, Tsukiyama-Kohara K, et al. Hepatitis C virus genotypes 1 and 2 respond to interferon-α with different virologic kinetics. J Infect Dis 1995;172:934-8.
9. Mita E, Hayashi N, Hagiwara H, et al. Predicting interferon therapy efficacy from hepatitis C virus genotype and RNA titer. Dig Dis Sci 1994;39:977-82.
10. Koizumi K, Enomoto N, Kurosaki M, et al. Diversity of quasispecies in various disease stages of chronic hepatitis C virus infection and its significance in interferon treatment. Hepatology 1995;22:30-5.
11. Enomoto N, Sakuma I, Asahina Y, et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus lb infection. N Engl J Med 1996;334:77-81.
12. Squadrito G, Leone F, Sartori M, et al. Mutations in the nonstructural 5A region of hepatitis C virus and response of chronic hepatitis C to interferon alfa. Gastroenterology 1997; 113:567-72.
13. Ibarrola N, Moreno-Monteagudo JA, Saiz M, et al. Response to retreatment with interferon-alpha plus ribavirin in chronic hepatitis C patients is independent of the NS5A gene nucleotide sequence. Am J Gastroenterol 1999;94:2487-95.
14. Saracco G, Rosina F, Abate ML, et al. Long-term follow-up of patients with chronic hepatitis C treated with different doses of interferona-2b. Hepatology 1993;18:1300-5.
15. Missale G, Bertoni R, Lamonaca V, et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest 1996;98:706-14.
16. Kawakami Y, Kobayashi Y, Kawasaki T, et al. Increased frequency of interferon-gamma-producing peripheral blood CD4+ T cells in chronic hepatitis C virus infection. Am J Gastroenterol 2000;95:227-32.
17. Nelson DR, Marousis CG, Ohno T, et al. Intrahepatic hepatitis C virus-specific cytotoxic T lymphocyte activity and response to interferon alfa therapy in chronic hepatitis C. Hepatology 1998;28:225-30.
18. Lohr HF, Schmitz D, Arenz M, et al. The viral clearance in interferon-treated chronic hepatitis C is associated with increased cytotoxic T cell frequencies. J Hepatol 1999;31:407-15.
19. Bradley D, McCaustland K, Krawczynski K, et al. Hepatitis C virus: Buoyant density of the factor VIII-derived isolate in sucrose. J Med Virol 1991;34:206-8.
20. Hijikata M, Shimizu Y, Kato H, et al. Equilibrium centrifugation studies of hepatitis C virus: Evidence for circulating immune complexes. J Virol 1993;67:1953-8.
21. Choo S-H, So H-S, Cho JM, et al. Association of hepatitis C virus particles with immunoglobulin: A mechanism for persistent infection. J Gen Virol 1995;76:2337-41.
22. Kanto T, Hayashi N, Takehara T, et al. Buoyant density of hepatitis C virus recovered from infected hosts: Two different features in sucrose equilibrium density-gradient centrifugation related to degree of liver inflammation. Hepatology 1994;19: 296-302.
23. Hino K, Fujii K, Korenaga M, et al. Correlation between relative number of circulating low-density hepatitis C virus particles and disease activity in patients with chronic hepatitis C. Dig Dis Sci 1997;42:2476-81.
24. Nagasaka A, Hige S, Matsushima T, et al. Differential flotation centrifugation study of hepatitis C virus and response to interferon therapy. J Med Virol 1997;52:190-4.
25. Sakai A, Kaneko S, Matsushita E, et al. Floating density of hepatitis C virus particles and response to interferon treatment. J Med Virol 1998;55:12-7.
26. Kanto T, Hayashi N, Takehara T, et al. Density analysis of hepatitis C virus particle population in the circulation of infected host: Implications for virus neutralization or persistence. J Hepatol 1995;22:440-8.
27. Ishida S, Kaito M, Kohara M, et al. Hepatitis C virus core particles detected by immunoelectron microscopy and optical rotation technique. Hepatol Res 2001;20:335-47.
28. Desmet VJ, Gerber M, Hoofnagle JH, et al. Classification of chronic hepatitis: Diagnosis, grading and staging. Hepatology 1994;19:1513-20.
29. Okamoto H, Sugiyama Y, Okada S, et al. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: Application to clinical surveys and tracing infectious sources. J Gen Virol 1992;73:673-9.
30. Simmonds P. Variability of hepatitis C virus. Hepatology 1995;21:570-83.
31. Fujita N, Kaito M, Ishida S, et al. Paraformaldehyde protects hepatitis C virus particles during ultracentrifugation. J Med Virol 2001;63:108-16.
32. Kanto T, Hayashi N, Takehara T, et al. Serial density analysis of hepatitis C virus particle populations in chronic hepatitis C patients treated with interferon-α. J Med Virol 1995;46: 230-7.
33. Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy. Science 1998;282:103-7.
34. Chiba J, Ohba H, Matsuura Y, et al. Serodiagnosis of hepatitis C virus (HCV) infection with an HCV core protein molecularly expressed by a recombinant baculovirus. Proc Natl Acad Sci USA 1991;88:4641-5.
35. Inoue Y, Suzuki R, Matsuura Y, et al. Expression of the amino-terminal half of the NS1 region of the hepatitis C virus genome and detection of an antibody to the expressed protein in patients with liver diseases. J Gen Virol 1992;73:2151-4.
36. Harada S, Suzuki R, Ando A, et al. Establishment of a cell line constitutively expressing E2 glycoprotein of hepatitis C virus and humoral response of hepatitis C patients to the expressing protein. J Gen Virol 1995;76:1223-31.
37. Shimizu Y, Hijikata M, Iwamoto A, et al. Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses. J Virol 1994;68:1494-500.
38. Thomssen R, Bonk S, Propfe C, et al. Association of hepatitis C virus in human sera with Β-lipoprotein. Med Microbiol Immunol 1992;181:293-300.
39. Trestard A, Bacq Y, Buzelay L, et al. Ultrastructural and physicochemical characterization of the hepatitis C virus recovered from the serum of an agammaglobulinemic patient. Arch Virol 1998;143:2241-5.